Actively Recruiting
A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors
Led by MediLink Therapeutics (Suzhou) Co., Ltd. · Updated on 2025-11-17
260
Participants Needed
1
Research Sites
109 weeks
Total Duration
On this page
Sponsors
M
MediLink Therapeutics (Suzhou) Co., Ltd.
Lead Sponsor
A
Akesobio
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study was designed to evaluate the efficacy and safety of YL201 in combination with Ivonescimab (AK112) in subjects with solid tumor.
CONDITIONS
Official Title
A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Advanced solid tumors for Phase 1 participants
- Extensive-stage small cell lung cancer, Non-AGA non-small cell lung cancer, or EGFR mutation non-small cell lung cancer for Phase 2 participants
- Eastern Cooperative Oncology Group performance status score of 0 or 1
- Body organ and bone marrow functions meet study requirements within 7 days before first dose
You will not qualify if you...
- Eligible for local curative treatment
- Prior treatment with drugs targeting B7-H3, including antibodies, ADCs, or CAR-T therapies
- Prior treatment with topoisomerase I inhibitors or ADCs containing these inhibitors
- Experienced grade 3 or higher immune-related adverse events during previous immune checkpoint inhibitor treatments
- History of bleeding disorders or significant bleeding symptoms within 4 weeks before randomization
- Tumor invasion of major blood vessels confirmed by imaging during screening
- Active autoimmune disease requiring systemic treatment
- Brain metastases or spinal cord compression
- Uncontrolled or significant cardiovascular diseases
- Clinically significant pulmonary diseases
- Known active pulmonary tuberculosis
- Other protocol-defined inclusion or exclusion criteria may apply
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China, 510060
Actively Recruiting
Research Team
M
MediLink Threrapeutics
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here